Safety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease

dc.authorid0000-0003-2013-3284
dc.authorid0000-0001-5836-4497
dc.contributor.authorAzari, Amir A.
dc.contributor.authorKaradağ, Remzi
dc.contributor.authorKanavi, Mozhgan Rezaei
dc.contributor.authorNehls, Sarah
dc.contributor.authorBarney, Neal
dc.contributor.authorKim, Kyungmann
dc.contributor.authorLongo, Walter
dc.date.accessioned2025-05-10T19:45:37Z
dc.date.issued2017
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractPurpose: To evaluate the treatment of autologous serum eye drops (ASED) on dry eyes in patients with graft-versus-host disease (GVHD).Methods: A retrospective chart review of 35 patients with a history of ocular GVHD following hematopoietic stem cell transplantation that used ASED to alleviate dry eye symptoms was performed. Patients were categorized into three different groups. If patients had available ophthalmic data before and after starting treatment was group 1 (n=14), had available ophthalmic data after starting treatment in group 2 (n=10) and had available ophthalmic data before treatment or did not have any data after starting treatment in group 3 (n=11). Data were collected on patient's age, gender, primary diagnosis, visual acuity and fluorescein corneal staining were collected on individual eyes in order to evaluate the efficacy of the ASED on alleviating dry eye-related signs and symptoms.Results: No adverse ocular effect from the ASED was found in our series (except one fungal keratitis). All patients reported either improvement (55%) or stability (45%) in their ocular symptoms upon the use of ASED. In patients with available data before and after starting treatment, the corneal staining score improved by a median of 1 (p=0.003) and the LogMAR visual acuity had a non-significant improvement.Conclusion: In our study, ASED used by patients with ocular GVHD were both safe and effective. ASED should be considered in patients with GVHD who suffer from dry eyes.
dc.description.sponsorshipNational Institutes of Health [P30-EY016665]; Research to Prevent Blindness; [P30 CA014520]
dc.description.sponsorshipThis work was supported by the National Institutes of Health grant P30-EY016665 (Core Grant for Vision Research) and an unrestricted department award from the Research to Prevent Blindness. This work was also supported by grant P30 CA014520. The authors have no financial interest in any of the products mentioned in the manuscript. None of the authors has any conflicts of interest in this study.
dc.identifier.doi10.1080/15569527.2016.1209770
dc.identifier.endpage156
dc.identifier.issn1556-9527
dc.identifier.issn1556-9535
dc.identifier.issue2
dc.identifier.pmid27380960
dc.identifier.scopus2-s2.0-84979503425
dc.identifier.scopusqualityQ3
dc.identifier.startpage152
dc.identifier.urihttps://doi.org/10.1080/15569527.2016.1209770
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11314
dc.identifier.volume36
dc.identifier.wosWOS:000399501400009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofCutaneous and Ocular Toxicology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectAutologous serum eye drops
dc.subjectcornea
dc.subjectdry eye
dc.subjectgraft-versus-host disease
dc.titleSafety and efficacy of autologous serum eye drop for treatment of dry eyes in graft-versus-host disease
dc.typeArticle

Dosyalar